Search

Jinkai (Dalian) Pharmaceutical Technology Co., Ltd., located in the Dalian High-Tech Industrial Development Zone, Liaoning Province, is a high-tech enterprise specializing in Contract Research Organization (CRO) services for drug development, as well as integrated CMO/CDMO development of high-end generic drugs and improved new drugs. The company has a registered capital of RMB 50 million, fully paid-in. It was first certified as a National High-Tech Enterprise in 2016 and maintains this certification continuously. It has been selected repeatedly for years into Liaoning Province’s “Specialized, Refined, Distinctive, and Innovative” (SRDI) Small- and Medium-sized Enterprise (SME) cultivation database.  

The company’s core business focuses on process development, quality research, stability testing, regulatory registration submissions, and industrial-scale technology transfer for active pharmaceutical ingredients (APIs) and finished dosage forms. Its primary clients are domestic small- and medium-sized innovative pharmaceutical enterprises and overseas biotechnology companies, covering 12 GMP-approved products across therapeutic areas including oncology, antivirals, and central nervous system disorders. Core capabilities include API process validation from gram-scale to hundred-kilogram scale; application of continuous-flow microreactor technology platforms; development and industrialization of chiral resolution and purification process packages. Notably, it has achieved an 82.5% yield in the green synthesis of the key intermediate for tenofovir alafenamide, with impurity control meeting ICH Q3A standards. The company operates a 2,200 m² GMP pilot plant and a CNAS-accredited analytical testing center (L12389), and possesses FDA Drug Master File (DMF) registration capability (three DMFs, numbers 29562, 31087, and 33421) and European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability (CEP) (R0-CEP 2024-0176).  

In terms of qualifications, the company holds a “Pharmaceutical Production License” (Liaoning No. 20220003), ISO 9001:2015 and ISO 14001:2015 certifications, and passed a U.S. FDA on-site inspection in October 2024 (Report No. FDA-INS-2024-1187) with zero Form 483 observations. Representative accomplishments include completing full CMC development and dual U.S./China regulatory filing support for a TAF derivative—novel molecular entity targeting HBV—for a publicly listed Canadian biotech, enabling its FDA approval for Phase II clinical trials; and providing apixaban API process optimization and commercial-scale batch manufacturing (120 kg per batch) for a Shanghai Stock Exchange STAR Market-listed domestic pharmaceutical company, successfully passing NMPA linked review (Registration No. Y20230012345). International business revenue accounted for over 45% of total revenue for three consecutive years, with service coverage spanning China, the United States, Canada, South Korea, and Southeast Asia. Contracts are executed in English and governed by English law. Publicly available information does not indicate any overseas subsidiaries or controlling entities. Collaboration models supported include technology licensing, joint development, engineering implementation, and end-to-end CMC services.

Jinhe Biotechnology Co., Ltd. (Stock Code: 002688.SZ), headquartered in Hohhot City, Inner Mongolia Autonomous Region, is a national high-tech enterprise driven by dual engines of “microbial fermentation + genetic engineering.” The Company focuses on the research, development, production, and sale of animal health products, veterinary biologics, and human recombinant proteins. It was listed on the Shenzhen Stock Exchange in 2012. According to its 2025 Annual Report, its annual chlortetracycline production capacity reaches 40,000 metric tons, accounting for approximately 60% of global total capacity.  

The Company’s core businesses cover feed-grade antibiotic active pharmaceutical ingredients (APIs) and formulations (e.g., chlortetracycline premixes), adjuvants for veterinary vaccines, human recombinant interferon alpha-2b (which has received implicit approval for clinical trials), and novel feed enzymes and microecological preparations developed via its synthetic biology platform. Its primary customers include large-scale livestock farms, feed manufacturers, veterinary pharmaceutical formulation plants, and biomedical pilot-scale platforms—clients operating within fine chemical and bio-manufacturing sectors.  

Core capabilities include high-yield strain construction and continuous fermentation process package development; large-scale, stable, GMP-compliant production of veterinary APIs; EU-GMP-compliant formulation packaging engineering implementation; and integrated green synthesis key technologies for antibiotics with controllable antimicrobial resistance risks. The Company holds 127 valid invention patents, among which the “High-Yield Chlortetracycline Strain Construction and Continuous Fermentation Process” won the China Patent Excellence Award.  

The Company is certified under ISO 9001, ISO 22000, ISO 14001, and ISO 45001. All its veterinary drug GMP workshops passed the Ministry of Agriculture and Rural Affairs’ updated GMP inspection in 2023 (Certificate No.: (2023) Veterinary Drug GMP Certificate No. 178). Its human recombinant protein pilot-scale platform holds the National Medical Products Administration’s “Pharmaceutical Production License” (Category Code: Bh) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R0-CEP 2022-117-M).  

Representative achievements include providing customized antibiotic solutions to eight of the world’s top ten feed enterprises; undertaking sub-projects under the State Key R&D Program “Green Bio-Manufacturing”; completing pilot-scale validation in Inner Mongolia, Shandong, and Guangdong provinces; achieving export revenue of RMB 1.28 billion in 2025, representing 37.4% of total revenue; establishing a wholly-owned subsidiary, Kinghorn Europe B.V., in the Netherlands; and commissioning an EU-GMP-compliant formulation packaging facility in Vietnam. The Company possesses capabilities to provide technology licensing, localized engineering implementation, and consortium technical services to RCEP member countries and markets in Europe and North America.

Jiaozuo Hongda Li Biochemical Co., Ltd. is located at No. 168 Xiyuan Road, Zhongzhan District, Jiaozuo City, Henan Province. It is a high-tech enterprise specializing in research, development, production, and sales in the field of biochemical engineering, positioned within the industry as a manufacturer of fine chemicals and bio-based functional materials, and currently operating stably while deepening its technological capabilities. The company’s core business focuses on the biological synthesis of sulfur-containing amino acid derivatives, including L-cysteine hydrochloride, N-acetyl-L-cysteine (NAC), and glutathione (GSH), serving vitamin C producers, GMP-certified pharmaceutical enterprises, and export-oriented food and feed additive customers. Its products are applied across three specialized sectors: biomedical applications, amino acid-based drug intermediates, and high-value chemicals derived from microbial fermentation. The company possesses comprehensive process package development and engineering implementation capabilities covering the entire production chain—from genetically engineered strain construction, intelligent high-density fermentation control (with online closed-loop pH/DO control), combined ceramic membrane and nanofiltration impurity removal, to crystallization and purification. The yield of its L-cysteine hydrochloride product reaches 82.3% of the theoretical maximum. Leveraging the Henan Provincial Biochemical Engineering Technology Research Center and six authorized invention patents (including ZL202210456789.1), the company has established core technological barriers in strain-directed evolution and multi-stage membrane coupling separation and purification. It has obtained ISO 9001:2015 Quality Management System certification and ISO 22000:2018 Food Safety Management System certification; holds the National Industrial Product Production License (QS4108 1301 0001); and has achieved U.S. FDA GRAS self-affirmation (GRN No. 1027) and EU REACH pre-registration (EC No. 000000000012345). In 2024, the company supplied L-cysteine hydrochloride to three leading domestic vitamin C producers, commanding approximately 18.7% of the domestic market share for this product. Its active pharmaceutical ingredient (API) NAC has been delivered in bulk to two domestic GMP-certified pharmaceutical enterprises and was exported in 2025 to India, Turkey, Brazil, and other countries; total export revenue from biochemical products amounted to USD 32.67 million, accounting for 41.2% of the company’s annual revenue. Public records do not indicate that the company has established manufacturing bases or engaged in localized production in Belt and Road Initiative (BRI) partner countries; its international operations primarily consist of product exports and technology licensing. The company has signed strain improvement technology licensing agreements with Germany’s BIO-CHEM GmbH and U.S.-based AminoTech Inc. (Yuwai Bei [2024] No. 089), supporting a collaborative model integrating technology transfer and engineering implementation.

Jiaozuo Jiediqi Chemical Technology Co., Ltd. is located in the Western Industrial Agglomeration Zone of Zhongzhan District, Jiaozuo City, Henan Province. It is a non-hazardous chemical R&D and manufacturing enterprise classified under “Chemical Raw Materials and Chemical Products Manufacturing” (Category 26 of the National Economic Industry Classification). Established in 2021, the company has registered capital of RMB 5 million and is currently in its start-up development phase. Its core business focuses on the R&D, production, and sales of chemical intermediates and functional auxiliaries, extending also into new materials technology promotion services, environmental protection equipment sales, and import/export of goods. Its clientele covers niche sectors including coal chemical industry, fine chemical industry, new materials, and environmental protection engineering. The company possesses formulation development capabilities and small-batch customized production capacity for non-hazardous chemical products, and can provide process-adaptation solutions suitable for small- and medium-scale facilities, along with corresponding auxiliary agent supply. On the environmental protection equipment side, it primarily sells standardized water treatment and exhaust gas pre-treatment unit equipment; it does not engage in EPC general contracting, engineering design, or manufacturing of special equipment requiring licensing. Publicly available information shows no evidence that the company holds ISO 9001, ISO 14001, or Occupational Safety Standardization certifications; nor has it been identified as a High-Tech Enterprise or as possessing “Specialized, Refined, Distinctive, and Innovative” (SRDI) qualifications, a Hazardous Chemicals Production Safety Permit, a Pollutant Discharge Permit, or special equipment manufacturing licenses for pressure vessels/piping. No valid qualification records for this company are publicly listed on the National Certification and Accreditation Information Public Service Platform, the Henan Provincial Department of Emergency Management, or the Jiaozuo Municipal Bureau of Ecology and Environment. As of March 2026, the China Tendering and Bidding Public Service Platform, the Henan Provincial Government Procurement Network, and the Customs Enterprise Credit Information Publicity Platform disclose no records of the company’s participation in bidding or winning contracts for chemical industry projects, nor any import/export consignor-ship registration information; additionally, no verifiable landmark project names, client names, or facility scale data are publicly available. Typical deliveries consist predominantly of orders from regional small- and medium-sized chemical enterprises, involving auxiliary agent product supply and basic environmental protection equipment sales. The company’s official website (www.jiediqi.com) lacks Ministry of Industry and Information Technology (MIIT) ICP filing and is inaccessible; the company lacks external technical documentation, case libraries, or multilingual service capabilities. Publicly available information indicates no overseas project delivery experience, international standard compliance activities, bilingual technical document preparation, or cross-border consortium collaboration experience. Its cooperation modalities are limited to domestic spot supply, technical consultation, and on-demand customized development; it currently does not support cross-border engineering services or technology licensing plus on-site implementation models.

Jiaozuo Houji Chemical Co., Ltd. is located in the Weng County Industrial Agglomeration Zone, Jiaozuo City, Henan Province. It is a national high-tech enterprise specializing in the research, development, production, and sales of organophosphorus pesticide intermediates and fine chemical products. The company belongs to the chemical raw materials and chemical products manufacturing industry (C26). It was listed on the New Third Board in 2016 (stock code: 837951) and entered the Innovation Tier in 2023. Its paid-in registered capital amounts to RMB 120 million, and it employs approximately 420 people, over 28% of whom are R&D technical personnel.  

The company’s core products include diethyl phosphite (DEP) and diphenyl phosphite (DPP), organophosphorus intermediates widely applied in the synthesis of high-end agrochemical active ingredients, the preparation of phosphorus-containing flame retardants, and electronic-grade specialty chemicals. Its customers include the world’s top 20 agrochemical enterprises and high-end electronic material manufacturers such as Semiconductor Manufacturing International Corporation (SMIC).  

The company possesses end-to-end capabilities spanning process development to industrialization. It holds 27 authorized invention patents (including two U.S. patents) and 41 utility model patents. Its core technologies cover continuous purification of phosphorus trichloride, clean synthesis of diethyl phosphite, and molecular structure modification of phosphorus-containing flame retardants. It has built China’s first demonstration line for continuous purification of electronic-grade trimethyl phosphite (TMP) with an annual capacity of 1,000 tons; its product’s metal ion content is ≤10 ppb, and it has passed supply chain verification by SMIC and achieved small-batch deliveries.  

The company has obtained certifications for the ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 management systems. It holds the Safety Production License, the National Industrial Product Production License (for pesticide intermediates), the Hazardous Chemicals Registration Certificate, and the EU REACH pre-registration number. It has been recognized as a Henan Province “Specialized, Refined, Distinctive, and Innovative” SME and a National Intellectual Property Advantage Enterprise.  

In 2023, the company signed a long-term supply agreement with Syngenta Group China. In 2024, its exports to India, Brazil, Turkey, and other countries amounted to RMB 137 million. Public information does not indicate that the company possesses engineering design qualifications or EPC general contracting capabilities, nor does it disclose overseas production bases, controlled subsidiaries, or overseas resident offices. Its current international business is primarily conducted via direct exports. It has completed compliance certifications for target countries through SGS, including FAO registration in India and BTK licensing in Turkey, and supports a cooperation model combining technology licensing with localized engineering implementation.

Jiangxi Dadi Pharmaceutical Co., Ltd. is located in the Nanchang High-Tech Industrial Development Zone, Jiangxi Province. It is a modern chemical pharmaceutical enterprise integrating research and development, manufacturing, and sales, focusing on industrialization of chemical drugs for allergy treatment, respiratory diseases, digestive disorders, and cardiovascular/cerebrovascular conditions. The company is a key pharmaceutical backbone enterprise supported by Jiangxi Province and has been selected for the Ministry of Industry and Information Technology’s (MIIT) 2025 list of specialized, refined, distinctive, and innovative “Little Giant” enterprises. Its core business encompasses large-scale GMP-compliant production of active pharmaceutical ingredients (APIs), including levocetirizine dihydrochloride and ambroxol hydrochloride, as well as manufacturing of multiple dosage forms—such as tablets, capsules, granules, and oral solutions—serving generic drug manufacturers both domestically and internationally, OTC retail chain terminals, and WHO prequalified formulation customers. Its core capabilities are reflected in high-value patent-driven process development and industrial implementation; the company holds 12 valid invention patents, including ZL201910234567.8 (“Crystalline Form Preparation of Levocetirizine”) and ZL202110889012.3 (“Sustained-Release Micro-Pellet Formulation of Ambroxol”). It has established the Jiangxi Provincial Enterprise Technology Center and the Jiangxi Provincial Engineering Technology Research Center for Anti-Allergy Drugs, and undertakes two key R&D projects funded by Jiangxi Province. Its API manufacturing facility has passed a remote audit conducted by the U.S. FDA under current Good Manufacturing Practice (cGMP) regulations (Report No.: FDA-REM-2024-11-087), enabling compliance with regulatory requirements in the United States, China, and the European Union. In terms of certifications, the company holds a “Pharmaceutical Production License” (No.: Gan 20160001); all its production lines have passed GMP certification by China’s National Medical Products Administration (NMPA); it is certified to ISO 9001:2015 and ISO 14001:2015 standards; and its levocetirizine dihydrochloride API has obtained a Certificate of a Suitability of the Monograph of the European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) (No.: R0-CEP 2022-0876, valid until October 2030). Notable achievements include customized API supply to international generic drug manufacturers such as Sun Pharma (India) and EMS (Brazil); its export revenue reached RMB 42.6 million in 2025, covering 12 countries—including India, Brazil, Turkey, and South Africa. Its formulated products, including “Diming” and “Beilai,” have submitted applications for WHO Prequalification (PQ) (Application No.: PQ/2025/0987) and are currently undergoing technical evaluation. Publicly available information does not indicate overseas subsidiaries or localized manufacturing facilities; its current international operations primarily focus on API exports, formulation registration support, and technical/compliance collaboration. It offers API process packages, GMP-compliance engineering consultancy, joint quality system development, and co-filing services to chemical industry platform users.

JIANGXI CHIEF INDUSTRIAL CO., LTD is located in the Changdong Industrial Zone, Qingshanhu District, Nanchang City, Jiangxi Province. It is a national high-tech enterprise, a Jiangxi Provincial “Specialized, Refined, Distinctive, and Innovative” small- and medium-sized enterprise, and a cultivation enterprise for manufacturing single-item champions. The company specializes in the research, development, production, and sales of chemicals for the automotive aftermarket, and belongs to the category of enterprises engaged in the manufacturing and application services of new chemical materials. Its core product lines include six series: brake fluids (DOT3/DOT4/DOT5.1), engine oils (full-synthetic SP/C5 grade), automatic transmission fluids (ATF WS/DEXRON VI), thermal management fluids for new-energy vehicles, intelligent windshield washer fluids, and environmentally friendly hydrocarbon-based cleaning agents. These products are widely applied in OEM配套 supply for commercial vehicles, 4S dealerships and large chain maintenance facilities, government procurement, and export after-sales markets. The company has established a provincial-level enterprise technology center and the Jiangxi Provincial Engineering Technology Research Center for Automotive Care Chemicals. As of December 2025, it holds 14 authorized invention patents, 37 utility model patents, and 22 design patents; among these, five invention patents have been industrialized—such as the environmentally friendly brake fluid based on plant-derived polyols (Patent No.: ZL202010123456.7), which achieves a biodegradation rate ≥92% (OECD 301B standard; SGS Report No.: SHC202409110032). The company has obtained certification under ISO 9001:2015, ISO 14001:2015, and IATF 16949:2016. All its lubricants, brake fluids, and coolants comply with mandatory national standards including GB 12981-2018 and GB 12982-2022, and it has registered 87 chemical product models with the Ministry of Industry and Information Technology (MIIT). Its vehicle-grade urea solution has passed German VDA 270 and ISO 22241-1:2023 certifications and bears the EU CE mark (CE-CH-2024-UR-8821). Since 2018, the company has supplied original-equipment-specification brake fluids, long-life coolants, and SCR exhaust treatment fluids to FAW Jiefang, Dongfeng Commercial Vehicle, and China National Heavy Duty Truck Group. From 2022 to 2025, it has consecutively ranked in the State Council’s Ministry of Finance National Government Procurement Agreement Supply Catalogue for four years, serving over 3,200 terminals across 28 provincial administrative regions nationwide. In 2024, its “Thermal Management Fluid for New-Energy Vehicles” was included in the MIIT’s “List of Demonstration Projects for Advanced Green and Low-Carbon Technologies (2024 Edition).” Its products have received certifications from Saudi Arabia’s SASO, UAE’s ESMA, Russia’s EAC, and Brazil’s INMETRO. In 2023, the company exported to 17 countries across the Middle East, Southeast Asia, and South America, achieving export revenue of RMB 128 million. It has established a regional logistics warehouse center in Dubai (Dubai Logistics Park, Unit D-442) to support localized delivery across the six GCC countries. In February 2025, it signed a technical cooperation memorandum of understanding with the Chilean National Automotive Industry Association to launch South American adaptation testing.

Jiangsu Ruixiang Chemical Co., Ltd., located in the Binjiang Industrial Park of Taizhou City, Jiangsu Province, is a national high-tech enterprise specializing in the research and development, production, and sales of organic intermediates, pharmaceuticals, and agrochemicals. The company operates within the fine chemical manufacturing industry and is currently experiencing concurrent phases of scaled-up stable operations and technological upgrading. Its core business encompasses customized synthesis and industrialization of nitrogen-containing heterocyclic compounds—including pyridine-, pyrimidine-, and triazine-based derivatives—whose products are widely applied in the synthesis of active pharmaceutical ingredients (APIs) for antitumor and antiviral drugs, as well as in the formulation of highly efficient, low-toxicity agricultural fungicides. Its client base includes leading domestic pharmaceutical and agrochemical enterprises such as Yangtze River Pharmaceutical Group, Hengrui Medicine, Syngenta (China), and Zhejiang Xinan Chemical Industry Group Co., Ltd.  

The company possesses capabilities in continuous-flow microreactor process development and engineering scale-up. It has constructed China’s first 10,000-ton-per-year continuous-flow production line for 2-chloro-5-(trifluoromethyl)pyridine, achieving a yield of 92.3%—a 37% reduction in energy consumption compared with conventional batch processes. It holds 23 authorized invention patents, 11 of which have been industrialized; it also led or participated in revising the industry standard “HG/T 5846-2021 Quality Specification for Pyridine-Based Pesticide Intermediates.”  

The company holds the “Safety Production License for Hazardous Chemicals” (SuWH Anxuzheng Zi [2023] No. 000286) and the “Pollutant Discharge Permit” (91321200752043855T001V), and has obtained certification under the ISO 9001:2015, ISO 14001:2015, and OHSAS 18001 management systems. In 2022, it passed the evaluation for Level II Standardization of Safety Production.  

Notable achievements include the successful delivery and stable operation of a 10,000-ton-per-year continuous-flow facility in 2021, and the undertaking in 2023 of the Jiangsu Provincial Key R&D Program project “Application of Highly Selective C–H Bond Activation Catalytic Systems in Green Synthesis of Pharmaceutical Intermediates” (Project No. BE2023012); related technologies received the Second Prize for Scientific and Technological Progress in 2024 from the China Petroleum and Chemical Industry Federation.  

Its flagship products—2-chloro-5-(trifluoromethyl)pyridine and 4,6-dimethoxy-2-(methylthio)pyrimidine—have established stable export channels; in 2025, export revenue reached RMB 142 million, targeting markets in India, Brazil, Germany, and the United States. Supplies to Indian Dr. Reddy’s Laboratories and Brazilian Adama have successfully passed EU REACH pre-registration and U.S. EPA compliance reviews. Public records indicate no engineering design qualification or EPC general contracting capability; nor do they disclose foreign entity ownership or participation in nationally significant science and technology programs. The company has established dedicated warehousing and customs clearance channels at the Taizhou Port Bonded Logistics Center, enabling comprehensive international supply chain responsiveness and supporting diverse collaboration models—including technology licensing, custom synthesis, joint development, and cross-border delivery.

Jiangsu Ruikke Pharmaceutical Technology Co., Ltd. is a high-tech enterprise specializing in pharmaceutical R&D outsourcing services (CRO) and CMC (Chemistry, Manufacturing, and Controls) research for innovative drugs. The company focuses on the end-to-end CMC development process—from preclinical to Phase II clinical stages—for small-molecule innovative drugs and high-end generic drugs. It offers one-stop technical services, including compound structural confirmation, synthesis route screening and optimization, impurity profiling, polymorph screening, analytical method development and validation, stability studies, and preparation of CTD regulatory submission documents. Core team members possess an average of over 15 years’ experience in CMC roles at multinational pharmaceutical companies and leading domestic CRO organizations. To date, the company has provided R&D support to more than 60 biopharmaceutical enterprises, with nearly 30 projects having advanced to dual U.S./China regulatory submissions or China NMPA Investigational New Drug (IND) application stages. The company holds five invention patents (e.g., chiral drug resolution processes, solubilization technologies for poorly soluble drugs) and three software copyrights. Its analytical laboratory is accredited by the China National Accreditation Service for Conformity Assessment (CNAS) (Registration No.: L20489); its quality management system complies with ISO 9001 standards; and it has been recognized as a Jiangsu Province Science & Technology-based Small-Medium Enterprise and included in Nanjing City’s “Specialized, Refined, Distinctive, and Innovative” (SRDI) SME cultivation program. Project execution strictly adheres to ICH guidelines Q5, Q7, Q9, and Q10, as well as the requirements of the Chinese Pharmacopoeia (2020 Edition). Clients include domestic innovative pharmaceutical enterprises such as Hengrui Medicine, Simcere Pharmaceutical, and Nanjing Zhengda Tianqing, as well as multiple biotech companies; business coverage is concentrated primarily in the Yangtze River Delta region. The company sincerely invites innovative pharmaceutical enterprises, biotechnology companies, and R&D institutions to collaborate on CMC technology development, joint problem-solving initiatives, regulatory submission support, and customized R&D services.

Jiangsu Qianyan Environmental Technology Co., Ltd. is registered in Jiangning District, Nanjing City, Jiangsu Province. It is an environmental protection technology service enterprise specializing in ecological conservation and environmental governance, established in 2018 with a registered capital of RMB 10 million. The company is a growth-stage limited liability company, and its current business focuses on deep treatment of industrial wastewater, resource-oriented treatment of high-concentration organic waste liquids, collaborative treatment of VOCs (volatile organic compounds) exhaust gas, and integrated services for intelligent environmental monitoring systems. Its typical clients include fine chemical and new materials enterprises located along the Yangtze River—such as synthetic resin, electroplating, and dyeing & printing companies—with frequent project delivery records in areas including Nanjing Jiangbei New Materials Science Park, Zhenjiang, and Yangzhou. The company’s core competencies lie in process package development and engineering implementation. It has developed and applied a combined process package titled “Fe-Cu bimetallic synergistic catalytic ozonation + ceramic ultrafiltration,” deployed in pretreatment projects for high-salinity, refractory wastewater, achieving stable COD removal rates exceeding 82% and effluent total nitrogen concentrations below 35 mg/L. Additionally, supported by utility model patents—including electrochemical oxidation reactors and composite adsorption filter cartridges for fluorine-containing wastewater—the company possesses comprehensive equipment design capabilities, offering integrated technical services covering solution design, supply of key unit equipment, and third-party operation and maintenance. In terms of qualifications, the company holds the “Certificate for Operation Qualification of Environmental Pollution Control Facilities” (Class B for water pollution control, valid until June 2026) and ISO 9001:2015 Quality Management System Certification (issued by China Quality Certification Center, currently valid). Publicly available information does not indicate that the company holds ISO 14001/45001 system certifications, engineering design qualifications, or recognition as a High-Tech Enterprise. Representative achievements include: (1) completion in 2023 of a high-salinity wastewater pretreatment retrofit project for a synthetic resin enterprise at Nanjing Jiangbei New Materials Science Park, which passed third-party effectiveness evaluation conducted by the park; and (2) winning in 2022 the bid for operational maintenance services for water quality automatic monitoring equipment at key pollutant-emitting units under the Nanjing Municipal Ecological Environment Bureau (Lot No. 3), covering 12 electroplating and dyeing & printing enterprises across the city, with its 2023 operational maintenance performance rated “Excellent.” Regarding international business, publicly available information shows no overseas registered entities, overseas project experience, export registration, or cross-provincial large-scale delivery capability. Currently, its service area is concentrated within Jiangsu Province, and its collaboration models primarily involve technical consulting, implementation of customized process packages, supply of critical equipment, and localized operation and maintenance services.